Drug Trial Radar · NCT07947134
A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
155
Planned (sponsor's estimate)
Start
Nov 25, 2026
Primary completion
Nov 16, 2029
Study completion Dec 28, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.
Conditions
- Solid Tumours
Interventions
GSK5864399Drug
GSK5864399 will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0Time frame: Up to approximately 155 weeks
- Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with changes in safety parametersTime frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severityTime frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with a change from baseline in body weightTime frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)Time frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)Time frame: Up to approximately 155 weeks
- Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to approximately 155 weeks
- Part 2: Confirmed Objective Response Rate (cORR)Time frame: Up to approximately 155 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.